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Over the last decade the availability of non-vitamin K antagonist oral anticoagulants 
(NOACs) has significantly changed daily clinical practice in managing 
thromboembolic risk in patients with atrial fibrillation (AF)(1). Guidelines for AF 
management have established that NOACs are the preferred treatment for the 
majority of AF patients (2); however recent data from “real-life” registries clearly 
shows that a significant proportion of patients are still treated with vitamin K 
antagonists (VKA)(3–5). Nevertheless, the role of NOACs still seems to be debated 
in some specific circumstances,  such as their role in the perioperative management 
of patients with AF, in relation to interruption or continuation of anticoagulation. 
 
The management of oral anticoagulation (OAC) therapy in the perioperative setting, 
has been long debated. Despite the absence of solid evidence, bridging OAC 
therapy with unfractioned heparin or low molecular weight heparin (LMWH) was 
commonly suggested (8). In 2015, the “Bridging Anticoagulation in Patients who 
Require Temporary Interruption of Warfarin Therapy for an Elective Invasive 
Procedure or Surgery” (BRIDGE) trial provided an answer to this important issue 
regarding warfarin(9), demonstrating that while patients undergoing bridging therapy 
with LMWH had a similar risk for thromboembolic complications, they were at 
significantly increased risk of major bleeding(9). Although, there has been some 
clarification about periprocedural management with warfarin, uncertainty still 
remained about periprocedural NOAC management, due to the lack of solid data and 
limited clinical experience. 
 
In this issue of Thrombosis and Haemostasis, Douketis and colleagues present a 
subgroup analysis on perioperative management and outcomes in AF patients 
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treated with warfarin or edoxaban, derived from the “Effective Anticoagulation with 
Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 
48” (ENGAGE AF-TIMI 48) trial(10). Of the 21,105 patients originally enrolled in the 
trial, 7193 (34.1%) required surgery or an invasive procedure, and were equally 
randomized to warfarin, edoxaban high dose (60 or 30 mg) and edoxaban low dose 
(30 or 15 mg), with no major differences across the three groups. The most common 
procedures were cardiac, gastrointestinal endoscopy, dental and 
electrophysiological. Among those undergoing elective procedures,  3116 (43.3%) 
had their anticoagulation interrupted, defined as warfarin/edoxaban stopped for 4 to 
10 days before the procedure, while 4077 (56.7%) were defined as “anticoagulant 
continued”, having stopped randomized treatment ≤3 days (or not stopped at all) 
before the procedure(10). A 30-day observation period was established to determine 
if there were differences in efficacy and safety between warfarin and the two doses 
of edoxaban in patients undergoing elective procedures, in patients with interrupted 
or continued anticoagulation treatment. 
 
In the anticoagulant interrupted group, rates of stroke or systemic embolism at 30 
days were 0.6%, 0.5% and 0.9% for the  warfarin, edoxaban high dose and 
edoxaban low dose groups, respectively (p=0.53 for differences across the groups). 
Corresponding figures in the anticoagulation-continued group were 1.1%, 0.7% and 
0.9%, with no significant between-group differences. Regarding the main safety 
outcome, major or clinically relevant non-major (CRNM) bleeding was reported in 
3.9%, 4.2% and 3.6% of patients receiving warfarin, edoxaban high dose and 
edoxaban low dose, respectively for the anticoagulation interrupted group, with no 
significant differences across the three treatment groups. Among patients who 
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continued anticoagulation, rates of major/CRNM bleeding in the three treatment 
arms (p=0.17) were 8.5%, 7.9% and 6.6%, respectively. Mortality rates  were similar 
across the three treatments whether or not anticoagulation was interrupted or 
continued(10). Results were comparable when analysed by type of procedure. 
 
These results, strengthened by the sample size and the independently adjudicated 
outcomes, demonstrate that edoxaban can be safely used and managed in patients 
undergoing elective procedures but that safety appears to be improved if OAC is 
interrupted. These results, in particular comparing NOACs and warfarin in major 
adverse outcomes, reinforces and strengthens previous observations (Table) from 
subgroup analyses of other NOACs phase III trials, in patients undergoing elective 
procedures(11–13). 
 
The current ESC AF guidelines do not provide specific recommendations about the 
management of OAC therapy in patients undergoing cardiovascular procedures and 
interventions, but suggest that these interventions can be performed safely on 
continued OAC and that on the basis of the BRIDGE trial discussed previously, 
bridging is not beneficial(2). 
 
More recently, the European Heart Rhythm Association (EHRA) released a 2018 
update to its practical guide on the use of NOACs in AF patients, which discussed 
this issue in greater detail(14), proposing perioperative management of OAC therapy 
as summarized in the Figure. The main points emphasised by the practical guide 
relate to patients’ baseline characteristics, in particular age and renal function, as 
well as the theoretical bleeding risk carried by the specific procedure, which need to 
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be taken into account when deciding whether to stop NOACs or not. Second,  given 
the predictable effect and rapid clearance of NOACs,  timely management of the 
planned procedure can take advantage of the window between dose 
administration(14). 
 
Taking these aspects into consideration, in procedures with a minor bleeding risk 
(dental or eye procedures, diagnostic endoscopy and superficial surgery), all NOACs 
can be continued safely up to the day before the procedure. No NOACs are 
administered the morning of the procedure and in those cases performed with no 
adverse events and with an immediate and complete haemostasis, NOACs can be 
restarted at the subsequent programmed dose but  not until 6 hours post-
procedure(14). 
 
In those procedures with a low bleeding risk (biopsies, electrophysiological or 
procedures with cardiac implantable devices, non-coronary angiographies), stop 
NOACs up to 24 hours before the procedure, and recommence based on the same 
conditions as for minor bleeding risk procedures(14). For all those subjects 
undergoing procedures with a high risk of bleeding (complex endoscopies, major 
surgeries) the recommendation is cessation of NOACs at least 48 hours before 
surgery, without bridging. In these situations, NOACs can be restarted 48 hours after 
the procedures (or longer in specific situations) or post- procedure low molecular 
weight heparin can be considered(14). 
 
In patients treated with dabigatran before the procedure, it is recommended to 
perform an accurate evaluation of renal function. In patients with a creatinine 
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clearance (CrCl) ≤80 mL/min, dabigatran should be stopped 12 hours earlier than in 
those with normal renal function (>80 mL/min); 24 hours earlier in patients with CrCl 
≤50 mL/min; 36 hours earlier in patients ≤30 mL/min. Similarly, in other specific 
situations in which the NOACs clearance could be prolonged it is recommended to 
stop the NOAC earlier(14). 
 
Another recent review about use NOACs in surgical scenarios, proposed similar 
recommendations, underlining the importance of stratifying the procedure predicted 
bleeding risk and of knowing the expected clearance time of the specific NOAC in 
the context of patient’s age and comorbidities(15). 
  
Notwithstanding the results provided by the NOAC phase III trials and expert 
recommendations, there is still a need for more specific perioperative data from 
adequately powered randomized studies to provide definitive evidence, given the 
need to balance thromboembolic and bleeding risks in AF management [ref]. To 
address this,  the “Perioperative Anticoagulant Use for Surgery Evaluation” (PAUSE) 
study has been initiated (ClinicalTrials.gov NCT02228798)(16),  a prospective study 
with three parallel cohorts (dabigatran, rivaroxaban and apixaban), aiming to enrol 
3291 patients undergoing surgical procedures, to establish if the suggested NOAC 
and patient specific interruption-resumption protocols are safe in the perioperative 
management of AF patients(16). Results from this study will provide stronger 
evidence about the management of NOACs in this specific setting. 
 
CONCLUSIONS 
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Despite the availability of data from subgroup analyses of the NOACs phase III trials 
and expert recommendations to reassure clinicians about the efficacy and safety of 
NOACs in the perioperative management of AF patients (based on their predictability 
of anticoagulation effect, rapid clearance of effect), robust evidence from RCTs is still 
required to further clarify the risks associated with interruption or continuation of 
NOACs.  Patient engagement, education and counselling are additional practical 
aspects to ensure safety whilst taking NOACs [ref]. 
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Table: Evidence about Periprocedural Management of NOACs from Phase III Trials 
STUDY YEAR NOAC PATIENTS PROCEDURES TREATMENTS RESULTS 
Healey (11) 2012 Dabigatran 4591 (25.3%) - D110: 1487 
D150: 1546 
W: 1558 
Stroke/SE 
D110 vs W: RR 1.05 95% CI 0.55-2.01  
D150 vs W: RR 1.01 95% CI 0.35-2.87 
Major Bleeding 
D110 vs W: RR 0.83 95% CI 0.59-1.17 
D150 vs W: RR 1.09 95% CI 0.80-1.49 
Sherwood (12) 2014 Rivaroxaban 4692 (33.0%) 7555 R: 2165 
W: 2527 
Stroke/SE 
R vs W: HR 0.74 95% CI 0.36-1.50 
Major Bleeding 
R vs W: HR 1.26 95% CI 0.80-2.00 
Garcia (13) 2014 Apixaban 5439 (29.9%) 9260 A: 2701 
W: 2738 
Stroke/SE 
A vs W: OR 0.60 95% CI 0.32-1.12 
Major Bleeding 
A vs W: OR 0.85 95% CI 0.61-1.16 
Legend: A= Apixaban; CI= Confidence Interval; D110= Dabigatran 110 mg; D150= Dabigatran 150 mg; HR= Hazard Ratio; 
NOAC= Non-vitamin K Antagonist Oral Anticoagulant; OR= Odds Ratio; R= Rivaroxaban; RR= Relative Risk; SE= Systemic 
Embolism; W= Warfarin.
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Figure Legends 
 
Figure: Perioperative Management for NOACs in AF Patients 
Legend: OAC treatment can be continued or restarted according to bleeding risk of 
the procedure (Solid blocks). In specific situations OAC can stopped later or 
restarted earlier if bleeding risk is considered particularly low or the procedure 
reported an immediate and complete haemostasis (Striped blocks). Under 
physicians’ judgement thromboprophylaxis with LMWH can be considered (Dotted 
blocks). *In patients taking Dabigatran, drug must be stopped as much earlier as 
lower is the renal function; AF= Atrial Fibrillation; LMWH= Low Molecular Weight 
Heparin; NOACs= Non-vitamin K Antagonist Oral Anticoagulants. 
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